Evidence map›Paper›PMID 42708480›Full record

ArticleJournal of Korean medical science2026

Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant

Hyeon Mu Jang, Seunghee Baek, So Yun Lim, Seongman Bae, Hyunkyung Park, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Je-Hwan Lee, Sung-Han Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hyeon Mu JangDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0003-0132-5261
Seunghee BaekDepartment of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7063-969X
So Yun LimDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-5647-3718
Seongman BaeDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-6375-3657
Hyunkyung ParkDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-5899-6400
Han-Seung ParkDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3577-0665
Yunsuk ChoiDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7983-8089
Jung-Hee LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-3127-0068
Je-Hwan LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7060-1675
Sung-Han KimDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. kimsunghanmd@hotmail.com.ORCID https://orcid.org/0000-0002-6596-8253

Funding

Korea Health Industry Development Institute RS-2025-02223138
6 · The paper itself

Abstract

backgroundUntil recent introduction of ceftazidime/avibactam (CAZ-AVI) to Korean hospitals in October 2023, alternative antibiotics had been used to treat carbapenem-resistant Enterobacterales (CRE) infection such as high-dose meropenem combination therapy with amikacin, tigecycline, and/or colistin. To compare the outcome of CRE bacteremia between CAZ-AVI (study group) and alternative antibiotics (comparator group) before/after the introduction of CAZ-AVI.

methodsWe retrospectively reviewed the adult patients with hematologic malignancy who had CRE bacteremia between January 2020 and July 2024.

resultsA total of 85 patients with CRE bacteremia were analyzed including 25 with CAZ-AVI and 60 with alternative antibiotics. In a time-dependent multivariable Cox model for negative conversion of bacteremia, CAZ-AVI (hazard ratio [HR], 2.475; 95% confidence interval [CI], 1.493-4.102;

conclusionCAZ-AVI showed higher rapid negative conversion for CRE bacteremia in patients with hematologic malignancy, compared to the alternative antibiotics.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsBacteremiaCarbapenem-Resistant EnterobacteriaceaeCeftazidimeEnterobacteriaceae InfectionsHematologic NeoplasmsAdultAgedDrug CombinationsFemaleHumansMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug CombinationsBacteremiaCarbapenemsDrug Resistance, MicrobialHematologic Neoplasms

Identifiers

PMID42708480
PMCPMC13550983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.